6 days Ago By ABMN Staff
XTX Topco Ltd purchased a new stake in OnKure Therapeutics ( NASDAQ:OKUR – Free Report ) in the 4th quarter, Holdings Channel.com reports. The fund purchased 18,633 shares of the company’s stock, valued at approximately $160,000.
Several other institutional investors also recently bought and sold shares of OKUR. Highbridge Capital Management LLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter worth $3,438,000. Aisling Capital Management LP acquired a new stake in shares of OnKure Therapeutics during the 4th quarter worth $762,000.
Geode Capital Management LLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter worth $659,000. Renaissance Technologies LLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter worth $408,000. Finally, Aldebaran Capital LLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter worth $392,000.
90.98% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth A number of analysts have recently commented on the company.
HC Wainwright dropped their price objective on OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, March 18th.
Oppenheimer dropped their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th.
Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.33.
OnKure Therapeutics Stock Performance OnKure Therapeutics stock opened at $2.54 on Tuesday. The stock’s 50 day moving average price is $4.
10 and its 200 day moving average price is $8.82. The firm has a market capitalization of $34.
13 million, a PE ratio of -0.21 and a beta of 0.35.
OnKure Therapeutics has a one year low of $2.45 and a one year high of $20.00.
OnKure Therapeutics ( NASDAQ:OKUR – Get Free Report ) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.
86) by ($0.51). On average, analysts forecast that OnKure Therapeutics will post -4.
05 earnings per share for the current fiscal year. OnKure Therapeutics Company Profile ( Free Report ) OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Featured Articles Want to see what other hedge funds are holding OKUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OnKure Therapeutics ( NASDAQ:OKUR – Free Report ). Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
